de Gramont A, Marpeau L, Demuynck B, Gonzalez-Canali G, Pigné A, Herbulot P, Lagadec B, Cady J, Couturier J Y, Delfau S
GERCOD, Hôpital Saint-Antoine, Paris.
J Gynecol Obstet Biol Reprod (Paris). 1991;20(3):381-5.
Intraperitoneal chemotherapy with a totally implantable catheter was performed in 42 patients with advanced ovarian cancer who received 178 courses of chemotherapy administered in 2 l of solution. Major complication was inflow obstruction due to fibrosis around the catheter observed in 10 patients, 23.8% of the cases. Other complications were: leakage 3 (7.1%), pain 3 (7.2%), infection 3 (7.1%) and rectal perforation 1 (2.4%). Overall, these complications occurred in 15 patients (35.7%) and were the cause of treatment interruption in 7 (16.7%). Outflow obstruction which occurred in 23 patients (54.8%), did not create discomfort and could not be considered as a complication. Despite the problems, intraperitoneal chemotherapy with a totally implantable catheter appeared feasible in at least 80% of the patients.
42例晚期卵巢癌患者采用完全植入式导管进行腹腔化疗，共接受了178个疗程的化疗，化疗药物溶于2升溶液中。主要并发症为导管周围纤维化导致的流入梗阻，10例患者出现该并发症，占病例数的23.8%。其他并发症包括：渗漏3例（7.1%）、疼痛3例（7.2%）、感染3例（7.1%）和直肠穿孔1例（2.4%）。总体而言，这些并发症发生在15例患者中（35.7%），并导致7例（16.7%）患者治疗中断。23例患者（54.8%）出现流出梗阻，但未引起不适，不能视为并发症。尽管存在这些问题，但至少80%的患者采用完全植入式导管进行腹腔化疗似乎是可行的。
